BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 30861200)

  • 1. Characteristics, risks, and outcomes of post-transplant lymphoproliferative disease >3 years after pediatric heart transplant: A multicenter analysis.
    West SC; Friedland-Little JM; Schowengerdt KO; Naftel DC; Pruitt Freeze E; Smith KS; Urschel S; Michaels MG; Kirklin JK; Feingold B
    Clin Transplant; 2019 May; 33(5):e13521. PubMed ID: 30861200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-transplantation lymphoproliferative disease in pediatric liver recipients in Taiwan.
    Hsu CT; Chang MH; Ho MC; Chang HH; Lu MY; Jou ST; Ni YH; Chen HL; Hsu HY; Wu JF
    J Formos Med Assoc; 2019 Nov; 118(11):1537-1545. PubMed ID: 30630698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients.
    Manlhiot C; Pollock-Barziv SM; Holmes C; Weitzman S; Allen U; Clarizia NA; Ngan BY; McCrindle BW; Dipchand AI
    J Heart Lung Transplant; 2010 Jun; 29(6):648-57. PubMed ID: 20304682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characteristics and outcomes of PTLD following intestinal transplantation.
    Wozniak LJ; Mauer TL; Venick RS; Said JW; Kao RL; Kempert P; Marcus EA; Hwang V; Cheng EY; Busuttil RW; McDiarmid SV; Farmer DG
    Clin Transplant; 2018 Aug; 32(8):e13313. PubMed ID: 29888807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-transplant lymphoproliferative disorder following pediatric heart transplantation.
    Mendoza F; Kunitake H; Laks H; Odim J
    Pediatr Transplant; 2006 Feb; 10(1):60-6. PubMed ID: 16499589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transplantation for congenital heart disease is associated with an increased risk of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in children.
    Offor UT; Bacon CM; Roberts J; Powell J; Brodlie M; Wood K; Windebank KP; Flett J; Hewitt T; Rand V; Hasan A; Parry G; Gennery AR; Reinhardt Z; Bomken S
    J Heart Lung Transplant; 2021 Jan; 40(1):24-32. PubMed ID: 33339556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
    J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients.
    Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
    Nephrol Dial Transplant; 2012 Jul; 27(7):2971-9. PubMed ID: 22273720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abdominal involvement in pediatric heart and lung transplant recipients with posttransplant lymphoproliferative disease increases the risk of mortality.
    Tai CC; Curtis JL; Szmuszkovicz JR; Horn MV; Ford HR; Woo MS; Wang KS
    J Pediatr Surg; 2008 Dec; 43(12):2174-7. PubMed ID: 19040929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post Transplant Lymphoproliferative Disorder risk factors in children: Analysis of a 23-year single-institutional experience.
    Bosse RC; Franke AJ; Paul Skelton W; Woody LE; Bishnoi R; Wang Y; Bhaduri-McIntosh S; Rajderkar D; Shih R; Dang NH; Slayton WB
    Pediatr Transplant; 2020 Aug; 24(5):e13747. PubMed ID: 32497335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and validation of a major adverse transplant event (MATE) score to predict late graft loss in pediatric heart transplantation.
    Almond CS; Hoen H; Rossano JW; Castleberry C; Auerbach SR; Yang L; Lal AK; Everitt MD; Fenton M; Hollander SA; Pahl E; Pruitt E; Rosenthal DN; McElhinney DB; Daly KP; Desai M;
    J Heart Lung Transplant; 2018 Apr; 37(4):441-450. PubMed ID: 28465118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-transplant lymphoproliferative disease in lung transplantation: A nested case-control study.
    Leyssens A; Dierickx D; Verbeken EK; Tousseyn T; Verleden SE; Vanaudenaerde BM; Dupont LJ; Yserbyt J; Verleden GM; Van Raemdonck DE; Vos R
    Clin Transplant; 2017 Jul; 31(7):. PubMed ID: 28383790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistent Epstein-Barr viral load in Epstein-Barr viral naïve pediatric heart transplant recipients: Risk of late-onset post-transplant lymphoproliferative disease.
    Das B; Morrow R; Huang R; Fixler D
    World J Transplant; 2016 Dec; 6(4):729-735. PubMed ID: 28058224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter survey on post-transplant lymphoproliferative disorders in pediatric heart transplant recipients: A case for development of consensus guidelines for screening, surveillance, and treatment?
    Weisert M; Harake D; Hede S; Russell M; Alejos J; Menteer J
    Pediatr Transplant; 2020 Aug; 24(5):e13730. PubMed ID: 32416037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statin therapy is not associated with improved outcomes after heart transplantation in children and adolescents.
    Greenway SC; Butts R; Naftel DC; Pruitt E; Kirklin JK; Larsen I; Urschel S; Knecht K; Law Y
    J Heart Lung Transplant; 2016 Apr; 35(4):457-65. PubMed ID: 26746989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality.
    Rabot N; Büchler M; Foucher Y; Moreau A; Debiais C; Machet MC; Kessler M; Morelon E; Thierry A; Legendre C; Rivalan J; Kamar N; Dantal J
    Transpl Int; 2014 Sep; 27(9):956-65. PubMed ID: 24964147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
    Hurwitz M; Desai DM; Cox KL; Berquist WE; Esquivel CO; Millan MT
    Pediatr Transplant; 2004 Jun; 8(3):267-72. PubMed ID: 15176965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 16-year multi-institutional study of the role of age and EBV status on PTLD incidence among pediatric heart transplant recipients.
    Chinnock R; Webber SA; Dipchand AI; Brown RN; George JF;
    Am J Transplant; 2012 Nov; 12(11):3061-8. PubMed ID: 23072522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphoproliferative disorders after paediatric heart transplantation: a multi-institutional study.
    Webber SA; Naftel DC; Fricker FJ; Olesnevich P; Blume ED; Addonizio L; Kirklin JK; Canter CE;
    Lancet; 2006 Jan; 367(9506):233-9. PubMed ID: 16427492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients.
    Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Yegitbasi M; Reinke P; Kebelmann-Betzig C; Hauptmann K; Gross-Wieltsch U; Hetzer R; Berger F
    Pediatr Transplant; 2009 Feb; 13(1):54-62. PubMed ID: 18518912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.